RT Journal Article
T1 Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
A1 Guerra, Ivan
A1 Perez-Jeldres, Tamara
A1 Iborra, Marisa
A1 Algaba, Alicia
A1 Monfort, David
A1 Calvet, Xavier
A1 Chaparro, Maria
A1 Mañosa, Miriam
A1 Hinojosa, Esther
A1 Minguez, Miguel
A1 Ortiz de Zarate, Jone
A1 Marquez, Lucia
A1 Prieto, Vanessa
A1 Garcia-Sanchez, Valle
A1 Guardiola, Jordi
A1 Rodriguez, G Esther
A1 Martin-Arranz, Maria Dolores
A1 Garcia-Tercero, Ivan
A1 Sicilia, Beatriz
A1 Masedo, Angeles
A1 Lorente, Rufo
A1 Rivero, Montserrat
A1 Fernandez-Salazar, Luis
A1 Gutierrez, Ana
A1 Van Domselaar, Manuel
A1 Lopez-SanRoman, Antonio
A1 Ber, Yolanda
A1 García-Sepulcre, Marife
A1 Ramos, Laura
A1 Bermejo, Fernando
A1 Gisbert, Javier P
K1 Adalimumab
K1 Anti-TNF
K1 Crohn’s disease
K1 Inflammatory bowel disease
K1 Infliximab
K1 Psoriasis
K1 Side effects
K1 Ulcerative colitis
AB Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect. To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes genéticos y Ambientales registry of Grupo Español de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with anti-TNFs without psoriasis were controls. Cox regression analysis was performed to identify predictive factors. Anti-TNF-induced psoriasis was reported in 125 of 7415 patients treated with anti-TNFs (1.7%; 95% CI, 1.4-2). The incidence rate of psoriasis is 0.5% (95% CI, 0.4-0.6) per patient-year. In the multivariate analysis, the female sex (HR 1.9; 95% CI, 1.3-2.9) and being a smoker/former smoker (HR 2.1; 95% CI, 1.4-3.3) were associated with an increased risk of psoriasis. The age at start of anti-TNF therapy, type of inflammatory bowel disease, Montreal Classification, and first anti-TNF drug used were not associated with the risk of psoriasis. Topical steroids were the most frequent treatment (70%), achieving clinical response in 78% of patients. Patients switching to another anti-TNF agent resulted in 60% presenting recurrence of psoriasis. In 45 patients (37%), the anti-TNF therapy had to be definitely withdrawn. The incidence rate of psoriasis induced by anti-TNF therapy is higher in women and in smokers/former smokers. In most patients, skin lesions were controlled with topical steroids. More than half of patients switching to another anti-TNF agent had recurrence of psoriasis. In most patients, the anti-TNF therapy could be maintained.
PB Oxford University Press
YR 2016
FD 2016-01-20
LK http://hdl.handle.net/10668/9886
UL http://hdl.handle.net/10668/9886
LA en
NO Guerra I, Pérez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, et al. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. Inflamm Bowel Dis. 2016 Apr;22(4):894-901
DS RISalud
RD Apr 8, 2025